Skip to main content

Table 1 Characteristics of the patients (n = 20)

From: Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation

   Mean ± S.D. Median Range
Age (year)   31.8 ± 7.0 31 18 – 44
Sex (male/female) 15/5    
Body Weight (kg)   67.0 ± 12.5 65.0 45.5 – 91.8
Body surface area (m2)   1.8 ± 0.2 1.8 1.4 – 2.1
Body mass index (kg/m2)   23.2 ± 3.3 23.1 15.5 – 28.8
Diagnosis     
  ALL 17    
  AML 2    
  ANKL 1    
Disease status at SCT     
  CR1 14    
  CR2 1    
  non CR 4    
  relapse 1 1    
Donor     
  MRD 6    
  MUD 7    
  MMRD 1    
  MMUD 6    
Stem cell source     
  Bone marrow 15    
  Peripheral blood stem cells 3    
  Umbilical cord blood 2    
GVHD Prophylaxis     
  CSP + MTX 9    
  TAC + MTX 11    
Laboratory data     
  Alb (g/dL)   4.0 ± 0.4 4.0 2.8 – 4.9
  T-pro (g/dL)   6.0 ± 0.4 5.8 5.4 – 7.0
  BUN (mg/dL)   10.3 ± 3.0 10.5 5.0 – 15.0
  Scr (mg/dL)   0.6 ± 0.2 0.6 0.3 – 1.0
  T-bil (mg/dL)   0.7 ± 0.3 0.7 0.4 – 1.7
  AST (IU/L)   35.0 ± 31.4 21.0 9.0 – 125
  ALT (IU/L)   45.6 ± 54.6 32.0 5.0 – 251
  1. ALL indicates acute lymphoblastic leukemia, AML acute myelogenous leukemia, ANKL aggressive NK cell leukemia, SCT stem cell transplantation, CR complete remission, MRD HLA–matched related donor, MUD HLA-matched unrelated donor, MMRD mismatched related donor, MMUD mismatched unrelated donor, CSP cyclosporin A, MTX methotrexate, TAC tacrolimus, Alb albumin, T-pro total protein, BUN blood urea nitrogen, Scr serum creatinine, T-bil total bilirubin, AST asparatate aminotransferase, ALT alanine aminotransferase